Who owns VYNE THERAPEUTICS INC?
- Ticker: VYNE
- CUSIP Number: 92941v308
Tip: Access positions for across all investors
Analyze quarterly positions in Vyne Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vyne Therapeutics stock
Who bought or sold VYNE THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Nantahala Capital Management | 2.0M | $1.2M | 100% | Mar 2026 |
|
| Lynx1 Capital Management | 1.6M | $973k | 100% | Mar 2026 |
|
| Shay Capital | 1.6M | $962k | 100% | Mar 2026 |
|
| Frigate Ventures | 1.2M | $743k | -2% | Mar 2026 |
|
| ADAR1 Capital Management | 1.1M | $636k | 319% | Mar 2026 |
|
| T3 Companies | 945k | $565k | 100% | Mar 2026 |
|
| Braidwell | 916k | $547k | 100% | Mar 2026 |
|
| Citadel Advisors | 514k | $307k | 1585% | Mar 2026 |
|
| KVP Capital Advisors | 501k | $299k | 0% | Mar 2026 |
|
| Two Sigma Investments | 426k | $255k | 94% | Mar 2026 |
|
| Acadian Asset Management | 382k | $228k | -40% | Mar 2026 |
|
| Geode Capital Management | 323k | $193k | 43% | Mar 2026 |
|
| Vanguard Group | 315k | $182k | 65% | Dec 2025 |
|
| Ikarian Capital | 265k | $158k | 0% | Mar 2026 |
|
| Vanguard Capital Management | 265k | $158k | 100% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 183k | $110k | 100% | Mar 2026 |
|
| UBS Group | 180k | $108k | 186% | Mar 2026 |
|
| Rangeley Capital | 118k | $71k | 18% | Mar 2026 |
|
| Susquehanna International | 100k | $58k | 74% | Dec 2025 |
|
| Jane Street | 96k | $57k | 32% | Mar 2026 |
|
| Boothbay Fund Management | 81k | $49k | 0% | Mar 2026 |
|
| XTX Topco | 79k | $46k | 100% | Dec 2025 |
|
| BlackRock | 44k | $27k | 0% | Mar 2026 |
|
| FNY Investment Advisers | 35k | $20k | 40% | Mar 2026 |
|
| Hrt Financial | 28k | $16k | 100% | Mar 2026 |
|
| Virtu Financial | 25k | $15k | 100% | Dec 2025 |
|
| Northern Trust | 23k | $13k | 0% | Dec 2025 |
|
| Commonwealth Equity Services | 18k | $11k | 0% | Mar 2026 |
|
| State Street Corporation | 16k | $9.1k | 0% | Dec 2025 |
|
| Harvest Investment Services | 11k | $6.4k | 0% | Dec 2025 |
|
| Tower Research Capital | 3.6k | $2.1k | -1% | Dec 2025 |
|
| Acorn Capital Advisors | 1.4k | $827.070000 | -100% | Dec 2025 |
|
| Mb, Levis & Associates | 1.0k | $621.997500 | 0% | Mar 2026 |
|
| Vanguard Global Advisers | 1.0k | $599.990400 | 100% | Mar 2026 |
|
| Northwestern Mutual Wealth Management Company | 800.00 | $478.000000 | 0% | Mar 2026 |
|
| Hurley Capital | 561.00 | $334.973100 | 0% | Mar 2026 |
|
| CWM | 500.00 | $0 | 0% | Dec 2025 |
|
| Centerpoint Advisors | 350.00 | $0 | 0% | Mar 2026 |
|
| Wells Fargo & Company | 65.00 | $39.000000 | 0% | Mar 2026 |
|
| Morgan Stanley | 43.00 | $25.800000 | 0% | Mar 2026 |
|
| Truvestments Capital | 25.00 | $15.000000 | 0% | Mar 2026 |
|
| Royal Bank of Canada | 15.00 | $0 | -99% | Mar 2026 |
|
| Newbridge Financial Services Group | 10.00 | $6.000000 | 0% | Mar 2026 |
|
| Motiv8 Investments | 1.00 | $0 | 100% | Dec 2025 |
|
Who sold out of Vyne Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| None | Dec 2025 | 1.6M | $942k |
| Two Sigma Advisers | Dec 2025 | 163k | $95k |
| Bridgeway Capital Management | Sep 2025 | 77k | $26k |
| GSA Capital Partners | Dec 2025 | 54k | $31k |
| Jpmorgan Chase & Co | Sep 2025 | 146.00 | $48.661800 |